Biotech laser-fo­cused on a sin­gle tar­get nabs $105M for fi­bro­sis, can­cer tri­als

Rober­to Ia­cone could sense a shift in sen­ti­ments as he went about rais­ing a Se­ries C for Alen­tis Ther­a­peu­tics, his Basel, Switzer­land-based biotech.

Where­as plat­form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER